Blue Apron Holdings Inc. (NYSE: APRN) missed revenue and earnings estimates for the third quarter of 2019. The consensus estimate was for a loss of $1.98 per share on revenue of $106.8 million. The stock was down 0.56% in premarket hours on Thursday.
Total revenues fell 34% to $99.5 million compared to the same period last year, reflecting a reduction in marketing spend while focusing on marketing efficiency and targeting high affinity customers.
Net loss was $26.2 million, or $1.99 per share, compared to $33.9 million, or $2.64 per share, last year.
CEO Linda Findley Kozlowski said, “We’re pleased to see the continued strengthening of our customer base with year-over-year improvements in certain key customer metrics in the third quarter. We continue to believe that the potential for Blue Apron remains significant and that with the execution of our strategy, we will achieve our 2020 growth targets.”
During the quarter, orders dropped 34% while the number of customers decreased 40%. However, the average order value improved to $57.60 from $56.79 last year. Average revenue per customer also improved to $258 from $233 in the year-ago period.
Adjusted EBITDA improved $5.6 million year-over-year to a loss of $13.2 million in the third quarter, versus a loss of $18.8 million in the prior-year period, reflecting the company’s continued focus on expense management and operational efficiencies.
Marketing expense, as a percentage of net revenue, was 12.2%, compared to 15.4% in the prior-year period. This decrease was due to the company’s strategy to focus on the most efficient marketing channels and customers with high affinity.
Capital expenditures totaled $1.1 million for the quarter. Cash and cash equivalents was $85.9 million as of September 30, 2019.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on